Search jobs 10-Jan-2021 Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
–
Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 –
–
2021 Net Product Revenue Guidance of $950 million to $1,050 million –
– Corporate priorities for 2021 include potentially filing supplemental New Drug Applications for cabozantinib in three additional indications –
– Presentation and webcast at 2021 J.P. Morgan Healthcare Conference on Monday, January 11th at 5:20 PM EST / 2:20 PM PST –
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an updat
Global Ovarian Cancer Drug Market Growth Factors And Future openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
Published: Dec 21, 2020
ALAMEDA, Calif. (BUSINESS WIRE) Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX
®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 – 0.36; p
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
REDWOOD CITY, Calif. and WUHAN, China, Dec. 16, 2020 XWPharma Ltd. today announced that Michael M. Morrissey, Ph.D. has been appointed to the company’s Board of Directors. Dr. Morrissey brings extensive experience as a scientist, leader of highly productive Research and Development organizations, and chief executive officer of a fully-integrated, widely respected biopharma company.
“We are very excited to welcome Mike to our Board,” said Leonard Blum, XWPharma President and CEO. “As a seasoned R&D and company leader, his perspective will be invaluable as we prioritize the multiple high potential opportunities our research unit has identified and navigate the evolving landscape of creating first of their kind therapeutics for patients suffering from CNS disorders with compelling unmet needs.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
XWPharmaDecember 16, 2020 GMT
REDWOOD CITY, Calif. and WUHAN, China, Dec. 16, 2020 (GLOBE NEWSWIRE) XWPharma Ltd. today announced that Michael M. Morrissey, Ph.D. has been appointed to the company’s Board of Directors. Dr. Morrissey brings extensive experience as a scientist, leader of highly productive Research and Development organizations, and chief executive officer of a fully-integrated, widely respected biopharma company.
“We are very excited to welcome Mike to our Board,” said Leonard Blum, XWPharma President and CEO. “As a seasoned R&D and company leader, his perspective will be invaluable as we prioritize the multiple high potential opportunities our research unit has identified and navigate the evolving landscape of creating first of their kind therapeutics for patients suffering from CNS disorders